U.S. markets closed
  • S&P 500

    3,298.46
    +51.87 (+1.60%)
     
  • Dow 30

    27,173.96
    +358.56 (+1.34%)
     
  • Nasdaq

    10,913.56
    +241.26 (+2.26%)
     
  • Russell 2000

    1,474.91
    +23.09 (+1.59%)
     
  • Crude Oil

    40.04
    -0.27 (-0.67%)
     
  • Gold

    1,864.30
    -12.60 (-0.67%)
     
  • Silver

    22.99
    -0.21 (-0.91%)
     
  • EUR/USD

    1.1637
    -0.0038 (-0.33%)
     
  • 10-Yr Bond

    0.6590
    -0.0070 (-1.05%)
     
  • GBP/USD

    1.2744
    -0.0008 (-0.06%)
     
  • USD/JPY

    105.5000
    +0.0980 (+0.09%)
     
  • BTC-USD

    10,744.47
    +47.48 (+0.44%)
     
  • CMC Crypto 200

    230.19
    +12.36 (+5.67%)
     
  • FTSE 100

    5,842.67
    +19.89 (+0.34%)
     
  • Nikkei 225

    23,204.62
    +116.82 (+0.51%)
     

Arbutus to Participate in Upcoming Investor Conferences

WARMINSTER, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company will be participating in the following investor conferences in October 2019:

Cantor Fitzgerald Global Healthcare Conference – New York
Friday, October 4, 2019, 1:10 PM ET
Presentation: William H. Collier

Chardan Genetic Medicines Conference – New York
Monday, October 7, 2019, 8:00 AM ET
Fireside Chat: William H. Collier and Dr. Gaston Picchio

Live webcasts of the presentations can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.  A replay of the webcasts will be available for 90 days following the live presentations.

About Arbutus

Arbutus Biopharma Corporation is a publicly-traded (ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.

Contact Information

Investors
William H. Collier
President and CEO
Phone: 604-419-3200
Email: ir@arbutusbio.com

Media
Pam Murphy
Investor Relations Consultant
Phone: 604-419-3200
Email: ir@arbutusbio.com